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Soleiman Kheiri4
Introduction. Diabetic nephropathy is the most prevalent cause 
of end-stage renal disease. Besides factors such as angiotensin II, 
cytokines, and vascular endothelial growth factor, uric acid may 
play a role as the underlying cause of diabetic nephropathy. We 
evaluated allopurinol effects on proteinuria in diabetic patients 
with nephropathy.
Materials and Methods. In a double-blinded randomized controlled 
trial on 40 patients with type 2 diabetes mellitus and diabetic 
nephropathy (proteinuria, at least 500 mg/24 h and a serum 
creatinine level less than 3 mg/dL), allopurinol (100 mg/d) was 
compared with placebo. Administration of antihypertensive and 
renoprotective drugs (angiotensin-converting enzyme inhibitors 
and angiotensin receptor blockers continued for both groups, 
without changes in dosage. Proteinuria was compared at baseline 
and 2 and 4 months between the two groups.
Results. Each group consisted of 9 men and 11 women. There were 
no difference between two groups regarding age, body mass index, 
duration of diabetes mellitus, systolic and diastolic blood pressure, 
fasting blood glucose, blood urea nitrogen, serum creatinine, serum 
potassium, and urine volume. Serum levels of uric acid (P = .02) 
and 24-hour urine protein (P = .049) were significantly lower in 
the patients on allopurinol, after 4 months of receiving allopurinol, 
compared with the control group.
Conclusions. Low-dose allopurinol can reduce severity of proteinuria 
after 4 months of drug administration, which is probably due to 
decreasing the serum level of uric acid. Thus, allopurinol can be 
administered as an adjuvant cost-effective therapy for patients 
with diabetic nephropathy.
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INTRODUCTION
Incidence of diabetic nephropathy is the same 
for type 1 and 2 diabetes mellitus (DM), and 
approximately 20% to 30% of diabetic patients 
are affected by nephropathy, 15 years after the 
beginning of DM.1 Hypertension and glomerular 
hyperfiltration contribute to the development of 
diabetic nephropathy.2,3 Activation of cytokines, 
profibrotic factors, inflammation, and vascular 
endothelial growth factor (VEGF) may also play 
some roles in occurrence and progression of diabetic 
nephropathy.4,5 Genetic susceptibility, age, poor 
glycemic control, some ethnic groups, obesity, and 
smoking are some other factors associated with 
diabetic nephropathy.6-9
A study carried out in Taiwan on patients with 
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type 2 DM demonstrated that serum level of uric 
acid in these patients directly correlated with the 
level of urinary albumin excretion, and the serum 
uric acid level of patients was higher compared 
with healthy people.10 Hyperuricemia may cause 
periglomerular vascular injury, glomerular 
hypertension, and reduced kidney perfusion, which 
consequently can lead to interstitial fibrosis.11-13 
In patients with type 2 DM, hyperuricemia may 
be accompanied by peripheral vascular disease, 
hypertension, hypertriglyceridemia, higher level 
of hemoglobin A1c, more severe albuminuria, 
lower glomerular filtration rate (GFR), and early 
start or rapid progression of diabetic nephropathy. 
Prevalence of hyperuricemia is especially high in 
diabetic women.14-16
A study on hypertensive rats demonstrated 
that allopurinol decreased renal injury, which 
could be due to inhibition of lipid peroxidation.17 
In hyperuricemic rats, elevation of serum renin 
and increased activity of cycloxygenase 2 in 
periglomerular arterioles were noted. Allopurinol, 
by decreasing the level of serum uric acid, reduced 
the histological changes and improved kidney 
function.13
Concerning the higher level of serum uric acid 
in diabetic patients and also its role in causing 
vascular and glomerular injuries, decreasing GFR, 
we evaluated the role of allopurinol in patients 
with type 2 DM and nephropathy. The aim of our 
study was to evaluate the effect of allopurinol in 
decreasing of proteinuria in type 2 diabetic patients 
with nephropathy.
MATERIALS AND METHODS
Patients
This was a double-blinded randomized controlled 
trial on 40 patients with type 2 DM and nephropathy 
(at least 500 mg/24 h) at the nephrology clinics 
of Isfahan, from August 2006 to May 2008. The 
study was approved by Isfahan University’s ethic 
committee. Patients were enrolled by simple random 
allocation to the study or control group, so that 
20 patients were included in each group. Sample 
size was determined 20 patients in each group, 
using a 5% significance level, a power of 80% and 
800 mg reduction in 24-hour urine protein of the 
control group.
To evaluate diabetic nephropathy, ophthalmologic 
evaluation was done for all patients. The inclusion 
criteria were an age over 18 years old, proteinuria 
greater than 500 mg/24 h, bilateral normal-size 
kidney on ultrasonography (9 cm to 12 cm), 
existence of diabetic retinopathy, and absence of 
systemic diseases or other causes of proteinuria 
based on physical examination and history. The 
exclusion criteria were as follows: administration 
of allopurinol for another reason, significant renal 
insufficiency (serum creatinine > 3 mg/dL or GFR 
< 25 mL/min), development of allopurinol side 
effects (elevated liver enzymes, cytopenia, and 
dermatitis), and uncooperativeness during the 
study. In nephrology clinics, 520 records of type 2 
diabetic patients were reviewed and 50 patients that 
met the inclusion criteria were selected, of whom 
44 patients agreed to enter the study. During the 
study, 4 patients (2 in each group) were excluded 
due to incompliance.
Methods
The patients received allopurinol tablet (100 
mg) or placebo, once per day, for 4 months. Both 
allopurinol and placebo were produced by the 
Mehr-daru Pharmaceutical Company, Iran. All 
of the patients who received antihypertensive 
drugs, angiotensin-converting enzyme inhibitors 
(ACEIs), or angiotensin receptor blockers (ARBs) 
continued them with the same schedule and 
dosage. If administration of new antihypertensive 
drugs were indicated, drugs without effects on 
proteinuria, such as beta blockers, were prescribed. 
All of the participants were using renoprotective 
drugs such as ACEIs and/or ARBs. Hyperglycemia 
treatment consisted of oral hypoglycemic agents 
(OHA) and/or insulin, which continued during 
the study with the same dose.
At baseline and also 2 and 4 months later, the 
participants were visited for evaluation of vital signs 
and results of laboratory tests. The following tests 
were performed for the patients: complete blood 
count, fasting blood glucose, blood urea nitrogen 
(BUN), serum creatinine, serum potassium, serum 
uric acid, serum aspartate aminotransferase and 
alanine aminotransferase, urinalysis, and 24-hour 
urine volume, protein, and creatinine. The blood 
count test was performed by H1 or SYSMEX 
(Tokyo, Japan), while fasting blood glucose, liver 
and kidney function parameters, and uric acid 
level were measured by an RA 1000 analyzer 
(Technicon Instrument, New York, NY, USA) 
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using Pars Azmoon kits (Tehran, Iran), and serum 
potassium, by Flame photometer (Eppendorf, 
Germany). The 24-hour urine protein was measured 
by trichloroacetic acid method, using a photometer 
(model ECOM-E G125, Eppendorf, Germany).
Statistical Analyses
The collected data were analyzed by descriptive 
indexes (mean ± standard deviation), the t test, the 
nonparametric Friedman test, and the Spearman 
correlation coefficient, using the SPSS software 
(Statistical Package for the Social Sciences, version 
13.0, SPSS Inc, Chicago, Ill, USA). To analyze the 
data, normal distribution test was performed; 
if the distribution was normal, then repeated 
measured analysis of variance was used. Otherwise, 
nonparametric tests including the Friedman and 
Mann-Whitney tests were used.
RESULTS
Table  1  demonst ra tes  the  demographic 
information of the patients. Each group consisted 
of 9 men and 11 women. The age of the patients was 
from 30 to 77 years with the mean of 57.7 ± 10.5 
years. The weight of the patients ranged from 
62 kg to 110 kg in study group and 43 kg to 100 
kg in the control group. The mean weight was 
significantly higher in the study group than in 
the control group (P = .045). Duration of DM was 
between 2 and 29 years (mean, 12.6 ± 6.7 years).
Based on repeated measure analysis of variance, 
patients in the study and control groups were not 
significantly different in terms of systolic and 
diastolic blood pressure, fasting blood glucose, 
blood urea nitrogen, serum creatinine, serum 
potassium, urine glucose, and urine volume levels 
during the study period (Table 2). The 24-hour 
urine creatinine level was significantly higher in 
the study group at baseline (P = .02), but there was 
no significant difference between the two groups 
at 2 and 4 months of the study.
Regression analysis showed that the higher 
level of urine creatinine concentration in the study 
group was due to the higher weight of this group. 
Generally, the mean urine creatinine in the study 
group was higher than that of the control group in 
all stages, but the difference was significant only 
at baseline. The two groups were not significantly 
different regarding serum levels of uric acid 
(P = .35), but at 4 months, serum uric acid levels 
of the study group were significantly lower than 
those of the control group (P = .02; Figure 1). At 
baseline and 2 months of the study, 24-hour urine 
protein concentration was not significantly different 
between the two groups, but at 4 months, urine 
protein of the study group was significantly lower 
than that of the control group (P = .049; Figure 2).
Finally, no adverse effects were reported by our 
patients in the allopurinol group during the study.
Variable Study Group Control  group
Number of patients 20 20
Gender
Male 9 9
Female 11 11
Age, y 56.3 ± 10.6 59.1 ± 10.6
Weight, kg 79.7 ± 12.7 71.1 ± 13.6
Body mass index, kg/m2 28.9 ± 5.1 26.8 ± 4.6
Diabetes mellitus duration, y 11.8 ± 5.7 13.3 ± 7.6
Table 1. Demographic Characteristics of Patients on Allopurinol 
and Placebo
Baseline At 2 Months At 4 Months
Variable Study Group
Control 
Group P
Study  
Group
Control 
Group P
Study 
Group
Control 
Group P
Systolic blood pressure, mm Hg 145.8 ± 11.3 147.3 ± 16.7 .74 143.8 ± 14.3 149.3 ± 14.7 .24 138.3 ± 9.5 142 ± 13.5 .32
Diastolic blood pressure, mm Hg 88.5 ± 8.6 86.0 ± 8.4 .36 87.8 ± 7.9 87.5 ± 9.1 .93 85.5 ± 7.9 85.3 ± 8.3 .92
Fasting blood glucose, mg/dL 178.4 ± 79.9 151.4 ± 61.7 .23 172 ± 68.9 146.4 ± 52.1 .19 158.3 ± 50.7 149.6 ± 46.3 .58
Blood urea nitrogen, mg/dL 25.9 ± 15.4 30.4 ± 16.0 .04 28.0 ± 15.1 32.5 ± 17.3 .38 38.5 ± 12.7 35.3 ± 24.6 .28
Serum creatinine, mg/dL 1.3 ± 0.45 1.5 ± 0.6 .31 1.3 ± 0.5 1.5 ± 0.6 .17 1.3 ± 0.5 1.6 ± 0.6 .18
Serum potassium, mg/dL 4.85 ± 0.41 4.67 ± 0.44 .18 4.79 ± 0.50 4.63 ± 0.46 .30 4.67 ± 0.35 4.71 ± 0.42 .75
Serum uric acid, mg/dL 5.96 ± 1.21 6.50 ± 2.20 .35 5.49 ± 0.50 6.37 ± 1.85 .06 5.31 ± 0.79 6.44 ± 1.97 .02
24-hour urine protein, mg 1756 ± 1047 1673 ± 997 .80 1268 ± 870 1688 ± 1152 .20 1011 ± 767 1609 ± 1071 .049
24-hour urine creatinine, mg 1203 ± 396 926 ± 322 .02 1154 ± 498 922 ± 338 .09 1091 ± 262 959 ± 355 .19
24-hour urine volume, mL 2383 ± 539 2152 ± 690 .25 2326 ± 538 2132 ± 592 .29 2234 ± 446 2306 ± 625 .68
Table 2. Clinical and Biochemical Parameters of Patients on Allopurinol and Placebo During the Study Period
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DISCUSSION
Various agents have been used for treatment 
of  diabet ic  nephropathy including ACEIs , 
ARBs, lipid-lowering agents, and protein intake 
restriction. Most studies have proved that ACEIs 
and ARBs are useful in the treatment of diabetic 
nephropathy.18-20 Administration of these drugs 
in microalbuminuria stages resolve albuminuria, 
but when microalbuminuria develops, these 
drugs  only  s low down the  progress ion of 
diabetic nephropathy and reduce the severity 
of proteinuria.21-23 Concerning the side effects of 
these drugs, including cough and hyperkalemia, 
it is not possible to administer these drugs to all 
patients or at full doses.
According to results of some studies, serum 
uric acid level of diabetic patients was higher than 
that of healthy people.10,12 Moreover, some studies 
indicated that hyperuricemia in diabetic patients 
was accompanied by vascular complications, 
albuminuria, and decreased GFR. Thus, decrease 
in serum uric acid level can probably be effective 
in treatment of diabetic nephropathy. To the 
best of our knowledge, there is no report on 
the therapeutic effect of allopurinol in diabetic 
nephropathy. Consequently, results of the current 
study cannot be compared with findings of other 
similar studies.
In the beginning of the study, the mean serum 
uric acid level was 5.9± 1.2 mg/dL and 6.5± 2.2 
mg/dL in study and control groups, respectively. 
The mean serum uric acid level in another study 
carried out on Taiwanese patients with type 
2 DM was 5.2 ± 1.6 mg/dL for patients with 
normalbuminuria, 5.6 ± 1.9 mg/dL for patients with 
microalbuminuria, and 6.7 ± 2.1 mg/dL for patients 
with macroalbuminuria.10 The mean serum level 
of uric acid in our patients was comparable with 
that of Taiwanese patients with macroalbuminuria.
Administration of allopurinol (100 mg/d) in our 
study group for 4 months resulted in significant 
decrease in serum uric acid level and also a significant 
decrease in proteinuria. It can be concluded that 
allopurinol, by lowering the serum uric acid, 
inhibited the effect of uric acid on glomeruli and 
kidney vasculatures, and consequently, reduced 
proteinuria. However, in short-term (after 2 months 
of administration of allopurinol), serum level of 
uric acid and severity of proteinuria in the study 
group did not significantly decrease, compared with 
the control group. Furthermore, allopurinol may 
have renoprotective effects via the mechanism of 
reducing the kidney microvasculature endothelial 
dysfunction. Thus, it can be concluded that low-
dose allopurinol (100 mg/d) can reduce severity 
of proteinuria, and possibly the progression of 
nephropathy, if administered for longer than 2 
months. Administering the drug at this dosage in 
the study did not bring about any adverse effects, 
and it seems that long-term treatment of patients 
with allopurinol is safe.
As all of the patients of the current study were 
receiving ACEIs or ARBs before and during, we 
can assume that the additional renoprotective 
effect (lowering the proteinuria severity) was not 
related to those drugs. Administration of allopurinol 
Figure 1. Mean serum levels of uric acid during the study in 
patients receiving allopurinol (study group) and placebo (control 
group).
Figure 2. Mean 24-hour urine levels of protein during the study 
in patients receiving allopurinol (study group) and placebo 
(control group).
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accompanied with those drugs can synergically 
increase the renoprotective effect.
CONCLUSIONS
In patients with diabetic nephropathy, allopurinol 
can be administered for treatment of diabetic 
nephropathy with no significant side effects. 
Considering the small sample size of this study, 
it is recommended that allopurinol effect on 
proteinuria be investigated further through studies 
at large scale with various doses of allopurinol 
and longer course of treatment in diabetic patients 
with nephropathy.
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